Kornimate/medical-research-clean huggingface dataset:
unilateral cutaneous ureterostomy - long term follow up

Conditions: Bladder Function

Summary: this observational study is aimed at exploring bladder function following temporary unilateral low loop cutaneous ureterostomy carried out in newborns suffering from severe congenital hydro-ureteronephrosis


Eligibility criteria:
inclusion criteria: * living patients * bilateral functioning kidneys * unilateral ureteral cutaneous diversion exclusion criteria: * dead patients * single kidney * high percutaneous ureteral diversion (e.g: cutaneous pyelostomies, bilateral cutaneous urinary diversion)

Keywords: bladder function cutaneous ureterostomy hydronephrosis
safety of manganese restriction in neonatal parenteral nutrition

Conditions: Infant, Newborn, Disease

Summary: participants will be \<= 32 weeks gestational age (ga) neonates randomized to parenteral nutrition (pn) prepared with standard dose trace elements or to pn prepared with standard trace elements minus manganese.

very preterm neonates \<= 32+6 weeks ga receiving pn will be randomized to receive their pn prepared with standard trace elements containing 5 mcg/kg/day of manganese, or to pn prepared with no added manganese. randomization assignment will be double masked. all participants will have whole blood manganese measurements at baseline, at 2 weeks of postnatal age, and at 8 weeks postnatal age. because manganese is present as a contaminant in many of the ingredients used to prepare neonatal pn, this study hypothesizes that neonates randomized to no added manganese in their pn will maintain whole blood manganese concentrations above the lower limit of normal.

Eligibility criteria:
inclusion criteria: * inborn admissions to the sharp mary birch hospital for women and newborns neonatal intensive care unit. * less than or equal to 32+6 weeks gestational age. * initiated on parenteral nutrition as decided by their attending neonatologist. exclusion criteria: * continuous exposure to routine care pn containing standard trace element for ≥ 4 hours. * congenital liver disease. * moribund status or imminent death. * any condition that in the judgment of the investigator or attending physician provider precludes participation because it could affect subject safety. * lack or refusal of informed consent

Keywords: manganese, parenteral nutrition, neonate, preterm, safety
identification and characterization of novel proteins and genes in head and neck cancer

Conditions: Head and Neck Cancer

Summary: through this study, we hope to learn more about the mechanisms, which may contribute to development and progression of head and neck cancer. the long-term goal of this study will be to develop new strategies and drugs for the diagnosis and treatment of head and neck cancer.


Eligibility criteria:
inclusion criteria: all patients undergoing surgery at stanford university for head and neck cancer. exclusion criteria: non-stanford patients.

Keywords: head and neck cancer
efficacy of ketamine in post anesthesia recovery room

Conditions: Pain, Postoperative; Ketamine Adverse Reaction; Pain, Refractory; Pain, Intractable; Pain, Acute

Summary: observational study to assess efficacy of iv ketamine bolus when used in the post anesthesia recovery unit for uncontrolled pain despite use of opioids.

in this observational study, the investigators will monitor all patients with significant pain after any non-cardiac surgical intervention at the university of alberta hospital. after receiving an adequate dose of potent opioids (hydromorphone, morphine), the participants will receive up to 0,2-0,25 mg/kg iv ketamine bolus. in our center these boluses are given with 10-20mg increments. the adequate dose of opioids will be determined by the attending anesthesiologist, depending on what patients received intraoperatively and on their comorbidities. pain scores will be assessed before and after administration of this drug. the incidence of any side effect after ketamine administration will be documented.

Eligibility criteria:
inclusion criteria: adult patients undergoing non cardiac surgery at university of alberta hospital meeting the following criteria: * age ≥ 18 * significant pain despite narcotics used in post-anesthesia care unit * ketamine ordered by attending anesthesiologist exclusion criteria: * patient refusal to receive ketamine * patients undergoing cardiac surgery * patients who received no narcotics * contra-indication to receiving ketamine (determined by attending anesthesiologist)

Keywords: pain score reduction reduction in pain scores post-operative pain ketamine use in recovery room recovery room ketamine recovery ketamine rescue
in it together: using acceptance and commitment therapy to treat distress among older adults with sensory loss and their spouses

Conditions: Sensory Loss (Impairment of Sight and/or Hearing)

Summary: impairments in hearing and/or vision are common in older age. having lived one's life as a fully sighted and hearing individual, older adults with sensory loss must come to terms with their declining capacity to interact with others and waning independence. there is ample research evidence showing that sensory loss (i.e., loss of hearing, vision or both) can be a distressful experience for older adults and their spouses, yet little has been done to understand what works in alleviating this distress or develop scalable cost-effective interventions to counter this distress or associated outcomes like depression, anxiety, poor quality of life, and lower relationship quality. in this project, the investigators will design and test an easy-to-administer, online intervention aimed at reducing emotional and marital distress in older adults with sensory loss and their spouses. the goal of the intervention will be to develop acceptance of the sensory loss through a series of acceptance and commitment therapy inspired educational, self-compassion, and therapeutic activities. in prior research, acceptance has been flagged as a promising factor on which to intervene to assist older couples' emotional and marital recovery in the context of sensory loss. thus, the investigators expect that the intervention should show encouraging results regarding the alleviation of distress in this group and contribute significantly to the psychosocial rehabilitation of older adults with sensory loss and their spouses.


Eligibility criteria:
inclusion criteria: * be 60 years of age or older * be able to read and write in danish * be in a romantic relationship of at least 1 year * live together with the partner (share housing) * feel either one self or one's partner has a sensory loss (hearing and/or sight) that affects day-to-day life. this sensory loss does not need to be confirmed by a health care provider. exclusion criteria: * less than 60 years of age * cannot read or write in danish * not in a romantic relationship * relationship length of less than 1 year * not living together with the partner (not share housing) * currently receiving psychological help (therapy/intervention)

Keywords: sensory loss hearing impairment sight impairment elderly couples age 60 or older online digital intervention acceptance and commitment therapy
clinical efficacy of novel jasminum-based calcium hydroxide medicament

Conditions: Necrotic Pulp; Acute Apical Periodontitis of Pulpal Origin

Summary: a triple-blind, parallel group, randomized trial with an allocation ratio of 1:1. participants randomly allocated into two groups a and b. in group a, nano-reinforced calcium hydroxide medicament was utilized while in group b, calcium hydroxide medicament without nanoparticles was used. post-operative pain was assessed after 4 hours, 24 hours, 48 hours, 72 hours, 96 hours.

this triple-blind parallel group, randomized clinical trial was conducted at the department of operative dentistry and endodontics, school of dentistry from april 24, 2024 to september 25, 2024. participants were randomly distributed into two groups by lottery method. a consecutive non-probability sampling technique was used. before initiating treatment, participants were briefed about the intervention and their preoperative pain score was recorded. in both groups, endodontic treatment was initiated under rubber dam isolation. access opening done and canals explored. working length taken by radiographic method and reconfirmed by an electronic apex locator. afterwards, canals were prepared till master apical file size f2 (4% taper). in group a, nano-reinforced calcium hydroxide medicament was placed while in group b, calcium hydroxide without nanoparticles was utilized. participants were instructed to rate their postoperative pain record after 4hrs, 24hrs, 48hrs, 72hrs and 96hrs.

Eligibility criteria:
inclusion criteria: * participants with good general health status * necrotic pulp with symptomatic apical periodontitis * single rooted teeth exclusion criteria: * non-restorable teeth * teeth associated with acute or chronic apical abscess * teeth with chronic periodontitis * teeth with anatomical complexities or complications like open apex, calcified canal, severe root dilaceration, root resorptive defects * participants who received antibiotic treatment during the last 3 months * pregnant females * participants on pre-treatment analgesics

Keywords: endodontic necrotic pulp apical periodontitis
tap vs qlb in patients after cesarean delivery

Conditions: Cesarean Section; Postoperative Pain

Summary: comparison of two types of analgesia after cesarean section all patients will be anesthetized with spinal technique. ultrasound-guided transversus abdominis plane or quadratus lumborum block to treat postoperative pain. postoperative pain will be measured with visual-analog scale (vas). 1, 2, 6 months after surgery each patient will be called to assess neuropathic pain with neuropathic pain symptom inventory (npsi).

written consent will be obtained before the cesarean section. only subarachnoidally anesthetized patients may participate in the study. pencil-point spinal needle and bupivacaine (marcaine heavy spinal 0.5 %) will be used. at the end of surgery ultrasound-guided regional block will be performed. each patient will be randomly allocated to one of the treated group: transversus abdominis plane block (tap) or quadratus lumborum (ql). patients receive 0.2 ml of local anesthetic solution (0.375 % ropivacaine) on each side. postoperative pain will be measured with vas (visual-analog scale) 2, 4, 8, 12 and 24 hours after the end of the operation. paracetamol, metamizole, ketoprofen may be given as required. whenever pain exceeds 40 (vas) 5 mg of morphine will be given intravenously (maximum two dosages per day). 1, 3, 6 months patients will be called to assess neuropathic pain. neuropathic pain symptom inventory (npsi) will be used.

Eligibility criteria:
inclusion criteria: * obtained consent * singleton pregnancy * subarachnoid anesthesia exclusion criteria: * coagulopathy * allergy to local anesthetics * depression, antidepressant drugs treatment * epilepsy * usage of painkiller before surgery * addiction to alcohol or recreational drugs

Keywords: transversus abdominis plane block quadratus lumborum block neuropathic pain
pilot study of simtuzumab in the treatment of liver fibrosis

Conditions: Liver Fibrosis

Summary: this study will evaluate the safety and tolerability of simtuzumab (gs-6624) in patients with fibrosis of the liver. up to 20 participants will be enrolled into two sequential cohorts. cohort 1 will consist of 10 participants who will receive simtuzumab every other week for a total of 3 infusions. participants in cohort 2 (10 subjects) will also receive simtuzumab every other week for a total of 3 infusions; the dose will depend on the safety and tolerability of simtuzumab seen in cohort 1. participants from both cohorts who have completed the main study will be allowed to continue on simtuzumab treatment for an additional extension period, and will receive up to 13 additional infusions of simtuzumab at a fixed dose of 700 mg for an additional 24 weeks.


Eligibility criteria:
inclusion criteria: * males and females 18 - 65 years of age * chronic liver disease of any etiology * stage 1-3 fibrosis by metavir score on a liver biopsy. * body mass index \<36 kg/m2 exclusion criteria: * any evidence of hepatic decompensation past or present * subjects currently abusing amphetamines, cocaine, opiates, or alcohol * clinically significant cardiac disease * history of cancer, other than non-melanomatous skin cancer, within 5 years prior to screening * systemic fungal, bacterial, viral, or other infection that is not controlled * use of systemic immunosuppressants within 28 days of the pre-treatment phase * use of approved therapy for hepatitis c or hepatitis b virus within 28 days of the pre-treatment phase * pregnant or lactating * history of bleeding diathesis within the last 6 months of study day 1

Keywords: gilead gilead sciences gsi liver fibrosis liver fibrosis
mhealth behavioural intervention to increase breast cancer screening rates among members of the public

Conditions: Breast Neoplasm Female

Summary: late-stage presentation of breast cancer cases are on the rise in malaysia. encouraging breast screening practices can assist in early breast cancer detection. literature has proven that behavior interventions in the form of behavior change health communication using social messaging applications is a viable strategy and potentially effective at motivating breast cancer screening among the public. such studies are scarce in the south east asian region, particularly in malaysia, which is the prime motivation for the current study, based on this promising prospect, a randomized controlled trial will be designed to study the effects of applying persuasive health communication materials to initiate behavior change among a group of malaysian women. materials are delivered in the form of a health communication program over a social messaging application to promote breast cancer screening practices, which is either a clinical breast examination, or a mammogram. the investigators hypothesize that malaysian women who are exposed to such materials that are designed based on behavior science and behavior change principles will be nudged and hence more likely to attend breast cancer screening compared to a control group.

this study involves a randomized controlled trial to asses the effectiveness of a health communication program using specifically designed materials using behavior science and behavior change principles. materials were designed based on findings derived from a scoping review and interviewing malaysian women through a series of qualitative interviews to determine the barriers and facilitators of attending breast cancer screening. the interview also investigated women's preferences for certain characteristics in a health message and health communication program that would motivate them to attend screening. participants in the main experimental group will be compared with a control group, and another group which undergoes a standard health communication program.

Eligibility criteria:
inclusion criteria: 1. malaysian women aged 40 years and above 2. possess a smartphone with the predetermined social messaging application (derived from phase 1 of study) installed. 3. have not been diagnosed with cancer before. exclusion criteria: 1. underwent clinical breast examination in the past 12 months. 2. mammogram screening in the past 2 years. 3. subjects who are deemed to have cognitive impairment and unable to provide consent to the study.

Keywords: mhealth breast cancer screening behaviour health communication randomised controlled trial behaviour change communication persuasive communication social messaging
the role of balneotherapy in older adults with chronic low back pain

Conditions: Chronic Low Back Pain; Older Adults; Health Resort Medicine; Quality of Life

Summary: the effectiveness of balneotherapy in relieving chronic low back pain has been scientifically proven. this project aims to study in what extent a balneotherapy program in são pedro do sul thermal baths influences chronic low back pain of individuals aged 65 and above, and in what order of magnitude it happens, on which domains (functional, psychological, biophysical and socioeconomic) and it's repercussions. for that, the investigators intended to carry out a project subdivided into two tasks. the first, and the most complex, with a holistic approach, will be carried out by a randomized controlled study (rct) with focus on the various biopsychosocial domains of patients with chronic lumbar pain. concerning the second task, another rct will be carried out aiming for statistically significant changes in the lumbar thermographic maps before and after treatment, as well as the theoretical framework of all the findings.


Eligibility criteria:
inclusion criteria: * patient aged 65 and over * low back pain with or without irradiation to the lower limbs with more than 3 months of evolution * imaging exam of the lumbar spine that excludes neoplastic pathology or severe structural misalignments * availability to carry out a 14-day treatment plan exclusion criteria: * can't read and write * history of fracture, surgery, infection or neoplasm in the spine * scoliosis with a cobb angle \>20 * lower limb muscle strength or vesico-sphincter changes * fever, history of recent violent trauma, unexplained weight loss, night sweats, or persistent night pain * others: unstable angina pectoris, poorly controlled hypertension, cardiac decompensation, respiratory failure, endocrine disorder, acute febrile condition, skin infections, fecal or urinary incontinence and psychosis or decompensated neurosis

Keywords: balneotherapy chronic low back pain older adults health resort medicine quality of life thermography crenotherapy balneology
transcutaneous vagal nerve stimulation to prevent tachyarrhythmias in patients early following myocardial infarction

Conditions: Myocardial Infarction; Tachyarrhythmia

Summary: among patients early following st-segment (st) elevation myocardial infarction, transcutaneous vagus nerve stimulation is associated with a reduce of the burden of premature ventricular contractions in the first 40 days post-myocardial infarction (mi). the above hypothesis will be tested with a randomized, prospective, parallel, single-blind clinical trial. the expected study duration is approximately 12 months from the time the first subject is enrolled (planned for june 2023) to the time of study's termination date (december 2024). patient enrollment is planned to take place at two major centers in greece. the researchers will obtain approval by the institutional review board (irb).


Eligibility criteria:
inclusion criteria: * male or female patients aged ≥18 years * st-elevation myocardial infarction which is treated with a primary percutaneous coronary intervention * signed written informed consent by the patient for participation in the study and agreement to comply with the medication and the follow-up schedule exclusion criteria: a patient will be excluded from the study if one or more of all the following criteria are present: * \< 3 months after prior ablation * patients on amiodarone * patients with known thyroid issues, on renal-dialysis * life expectancy of \< 12 months * complex congenital heart disease * cardiogenic shock * women who are pregnant (as evidenced by pregnancy test if pre-menopausal) * known channelopathy such as brugada syndrome, long qt syndrome, or catecholaminergic monomorphic ventricular tachycardia * symptomatic sinus bradycardia or sinus node dysfunction at baseline without an implantable pacemaker * complete heart block or trifascicular block without an implantable pacemaker * recurrent vasovagal syncope * pre-existing implantable cardioverter-defibrillator (icd) * secondary prevention indication for an icd (i.e. sustained ventricular arrhythmias occurring more than 48 hours after qualifying myocardial infarction (patients with ventricular arrhythmias occurring ≤48 hours of myocardial infarction, or with non-sustained ventricular tachycardia at any time, are not excluded)) * on the heart transplant list * recurrent unstable angina despite revascularisation (defined as ongoing chest pain or ischemic symptoms at rest or with minimal exertion despite adequate treatment with anti-anginal medications) * congestive heart failure new york heart association class iv, defined as shortness of breath at rest, which is refractory to medical treatment (not responding to treatment)

Keywords: transcutaneous vagal nerve stimulation
clinical outcomes and efficacy of left ventricular assist device for korean patients with cardiogenic shock

Conditions: Shock, Cardiogenic

Summary: retrospectively and prospectively enrolled patients with cardiogenic shock in domestic manifolds and investigated the current state of treatment and clinical features of cardiogenic shock in koreans and identified the factors that could improve the prognosis and the use of iabp and ecmo and to investigate its therapeutic effect.

1. the selection / exclusion criteria for persons with cardiogenic shock should be verified by medical records from january 1, 2014 before the approval date of each institution's clinical trial screening committee. 2. if a cardiogenic shock to the selection criteria is found in the emergency room, general ward, or intensive care unit of the participating institutions, enroll in this study and fill in the information according to the e-crf. 3. after 1, 6 and 12 months, visit the hospital for examination and procedures. the person in charge of the examination or the delegate of the examiner may follow the person by telephone or an outpatient visit.

Eligibility criteria:
inclusion criteria: 1. 19 years old or older 2. ① systolic blood pressure is less than 90mmhg for more than 30 minutes despite the fluid therapy, or use of pressure boosting agents is necessary. ② peripheral hypopnea (cold skin, urine less than 30 cc per hour, impaired consciousness, lactate ≥2.0 mmol / l) or a person with pulmonary edema. 3. causes of cardiogenic shock include acute myocardial infarction (including in coronary intervention), cardiomyopathy, myocarditis, pulmonary embolism, refractory ventricular tachycardia, shock during coronary intervention. 4. those voluntarily consenting to the medical records and the data necessary for the study during the entire study period. exclusion criteria: 1. other causes except for cardiogenic shock (low blood pressure, septic, obstructive shock) 2. shock with cardiac arrest outside the hospital 3. people with allergic reactions to anticoagulants such as heparin. 4. those who refused active treatment.

Keywords: shock, ivbp, ecmo, in hospital death